Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TNF Inhibitor Clear all
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 19, 2026, 6:20 AM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist

NCT00001475
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
IL-2 plus Anti-TNF or Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 19, 2026, 6:20 AM EDT
Enrolling by invitation Early Phase 1 Interventional

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

NCT05950724
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Etanercept Injection [Enbrel]
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed No phase listed Observational

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

NCT04798287
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, TNF Inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 6:20 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Azacytidine During Anti-tuberculosis Therapy

NCT03941496
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
Azacitidine Injection
Drug
Lead sponsor
Andrew Dinardo
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 19, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Humira Pregnancy Registry

NCT01086059
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 19, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

NCT00796809
View directory record Official record
Conditions
Coccidioidomycosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 19, 2026, 6:20 AM EDT
Completed No phase listed Observational

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

NCT01698515
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 19, 2026, 6:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

NCT05782335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Apremilast in Atopic or Contact Dermatitis

NCT00931242
View directory record Official record
Conditions
Atopic Dermatitis, Allergic Contact Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

NCT02092467
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
tofacitinib, adalimumab, etanercept
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
4,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
142
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

NCT02983227
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Glendale, Arizona • Covina, California • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

NCT02437253
View directory record Official record
Conditions
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated No phase listed Observational

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

NCT05814627
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
85
States / cities
Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

NCT00740103
View directory record Official record
Conditions
Crohn's Disease
Interventions
Semapimod
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Suwanee, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

NCT00771667
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 19, 2026, 6:20 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 6:20 AM EDT